The global incidence of HRAS-mutant tumors is approximately 230,000 per year- representing 7% of all RAS-mutant tumors.(1) Activating mutations in the HRAS oncogene have been described with varying prevalence across multiple cancer lineages including bladder, head and neck squamous cell cancer (HNSCC), lung, thyroid and melanoma.(2) Targeting RAS-mutant tumors remains challenging. The gene discussed is HRAS; the disease is melanoma.